Wanbury Limited (NSE:WANBURY)

Market Cap	8.15B -6.3%
Revenue (ttm)	6.53B +3.3%
Net Income	558.87M +30.0%
EPS	16.34 +29.9%
Shares Out	n/a
PE Ratio	14.58
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	132,335
Open	230.00
Previous Close	233.10
Day's Range	223.65 - 238.40
52-Week Range	161.50 - 358.85
Beta	0.16
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About Wanbury

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. It offers formulations for anti-infectives, pain and analgesics, gastroenterology, rheumatology, respiratory, gynecology, and central nervous system, as well as for vitamins, minerals, and nutrition. The company also provides API products for antidiabetics, antidepressants, anti-histaminic, anaesthetic, anti-inflammatory, anti-coagulant, GERD, and gastric ulcer therapy, as well as antitussives and analgesics. Its API por...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1988
• Employees: 1,200
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: WANBURY

Financial Performance

In fiscal year 2026, Wanbury's revenue was 6.50 billion, an increase of 8.35% compared to the previous year's 6.00 billion. Earnings were 661.35 million, an increase of 116.62%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 24, 2026

Data Sources Report a data error